Table 1 Laboratory parameters . Baseline... | American Society of Hematology

Table 1

Laboratory parameters

	Baseline	Hemodilution	30 min after trauma	60 min after trauma	120 min after trauma
Hemoglobin, g/L
Control	8.0 ± 0.5	7.5 ± 0.3*	4.6 ± 1.3	4.0 ± 0.9	2.5 ± 0.3
PCC35	8.0 ± 0.4	7.4 ± 0.4*	5.8 ± 0.7†	5.9 ± 0.6†	5.5 ± 0.8†
PCC50_DIC−	8.2 ± 0.4	7.5 ± 0.2*	5.5 ± 0.7	5.5 ± 0.5†	5.6 ± 0.6†
PCC50_DIC+	8.3 ± 0.5	7.3 ± 0.4*	3.6 ± 0.4‡§	3.5 ± 1.1‡§	2.8 ± 0.9‡§
Platelet count, × 10³/μL
Control	304 ± 32	110 ± 18*	100 ± 25	87 ± 28	71 ± 21
PCC35	280 ± 33	119 ± 10*	118 ± 19	114 ± 11†	106 ± 11†
PCC50_DIC−	290 ± 36	120 ± 8*	99 ± 14	86 ± 29‡	97 ± 22†
PCC50_DIC+	325 ± 44‡	115 ± 20*	81 ± 18‡	75 ± 23‡	40 ± 8†‡§
Fibrinogen, mg/dL
Control	322 ± 29	106 ± 15*	61 ± 24	55 ± 18	38 ± 18
PCC35	308 ± 32	110 ± 14*	87 ± 13†	87 ± 12†	79 ± 10†
PCC50_DIC−	323 ± 25	120 ± 22*	98 ± 17†	88 ± 15†	92 ± 12†
PCC50_DIC+	343 ± 24	114 ± 19*	43 ± 23‡§	32 ± 13‡§	< 20, ND
aPTT, s
Control	12 ± 1	19 ± 2*	23 ± 4	21 ± 3	25 ± 4
PCC35	12 ± 1	19 ± 2*	22 ± 2	21 ± 1	22 ± 2
PCC50_DIC−	11 ± 1	18 ± 1*	21 ± 2	21 ± 2	24 ± 2
PCC50_DIC+	11 ± 1	20 ± 2*	26 ± 2‡§	43 ± 14†‡§	> 300, ND
Antithrombin, %
Control	79 ± 6	36 ± 5*	29 ± 9	33 ± 6	25 ± 8
PCC35	88 ± 9†	39 ± 7*	38 ± 3†	39 ± 4†	41 ± 6†
PCC50_DIC−	79 ± 5	34 ± 3*	32 ± 6	38 ± 5†	40 ± 6†
PCC50_DIC+	93 ± 16†§	41 ± 8*	23 ± 7‡§	19 ± 4†‡§	21 ± 12‡§

	Baseline	Hemodilution	30 min after trauma	60 min after trauma	120 min after trauma
Hemoglobin, g/L
Control	8.0 ± 0.5	7.5 ± 0.3*	4.6 ± 1.3	4.0 ± 0.9	2.5 ± 0.3
PCC35	8.0 ± 0.4	7.4 ± 0.4*	5.8 ± 0.7†	5.9 ± 0.6†	5.5 ± 0.8†
PCC50_DIC−	8.2 ± 0.4	7.5 ± 0.2*	5.5 ± 0.7	5.5 ± 0.5†	5.6 ± 0.6†
PCC50_DIC+	8.3 ± 0.5	7.3 ± 0.4*	3.6 ± 0.4‡§	3.5 ± 1.1‡§	2.8 ± 0.9‡§
Platelet count, × 10³/μL
Control	304 ± 32	110 ± 18*	100 ± 25	87 ± 28	71 ± 21
PCC35	280 ± 33	119 ± 10*	118 ± 19	114 ± 11†	106 ± 11†
PCC50_DIC−	290 ± 36	120 ± 8*	99 ± 14	86 ± 29‡	97 ± 22†
PCC50_DIC+	325 ± 44‡	115 ± 20*	81 ± 18‡	75 ± 23‡	40 ± 8†‡§
Fibrinogen, mg/dL
Control	322 ± 29	106 ± 15*	61 ± 24	55 ± 18	38 ± 18
PCC35	308 ± 32	110 ± 14*	87 ± 13†	87 ± 12†	79 ± 10†
PCC50_DIC−	323 ± 25	120 ± 22*	98 ± 17†	88 ± 15†	92 ± 12†
PCC50_DIC+	343 ± 24	114 ± 19*	43 ± 23‡§	32 ± 13‡§	< 20, ND
aPTT, s
Control	12 ± 1	19 ± 2*	23 ± 4	21 ± 3	25 ± 4
PCC35	12 ± 1	19 ± 2*	22 ± 2	21 ± 1	22 ± 2
PCC50_DIC−	11 ± 1	18 ± 1*	21 ± 2	21 ± 2	24 ± 2
PCC50_DIC+	11 ± 1	20 ± 2*	26 ± 2‡§	43 ± 14†‡§	> 300, ND
Antithrombin, %
Control	79 ± 6	36 ± 5*	29 ± 9	33 ± 6	25 ± 8
PCC35	88 ± 9†	39 ± 7*	38 ± 3†	39 ± 4†	41 ± 6†
PCC50_DIC−	79 ± 5	34 ± 3*	32 ± 6	38 ± 5†	40 ± 6†
PCC50_DIC+	93 ± 16†§	41 ± 8*	23 ± 7‡§	19 ± 4†‡§	21 ± 12‡§

Data are mean ± SD.

ND indicates not detectable.

P < .05 versus each group over time.

P < .05 versus control.

P < .05 versus PCC35.

P < .05 versus PCC50_DIC−.